0000000000141547

AUTHOR

Carlo Carnaghi

showing 3 related works from this author

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

2018

Abstract Introduction Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty. Aim To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. Patients and methods Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th–75th IQR). Results Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3…

0301 basic medicineIndolesEndocrinology Diabetes and MetabolismNeuroendocrine tumorsPyrroleGastroenterologyTarget therapyEfficacyAntineoplastic Agent0302 clinical medicineEndocrinologyRetrospective StudieSunitinibPancreadiabetes and metabolismSunitinibGastroenterologyPancreatic NeoplasmMiddle AgedDiabetes and MetabolismNeuroendocrine TumorsTreatment OutcomeTolerabilityNeuroendocrine tumors; Pancreas; Progressive disease; Sunitinib; Target therapy; Endocrinology Diabetes and Metabolism; Hepatology; EndocrinologyItaly030220 oncology & carcinogenesisNeuroendocrine tumorsmedicine.drugHumanAdultmedicine.medical_specialtyAntineoplastic AgentsNeutropenia03 medical and health sciencesNeuroendocrine tumorInternal medicinemedicineHumansPyrrolesProgression-free survivalPancreasCancer stagingAgedRetrospective StudiesHepatologybusiness.industryProgressive diseasemedicine.diseasePancreatic Neoplasms030104 developmental biologyNeuroendocrine tumors; pancreas; progressive disease; Sunitinib; target therapy; endocrinology; diabetes and metabolism; hepatology; endocrinologyIndolebusinessProgressive diseasePancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
researchProduct